{"id":985111,"date":"2026-07-27T13:56:55","date_gmt":"2026-07-27T17:56:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/"},"modified":"2026-07-27T13:56:55","modified_gmt":"2026-07-27T17:56:55","slug":"capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/","title":{"rendered":"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, July  27, 2026  (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR) complied with federal securities laws.\u00a0On July 27, 2026, <em>STAT<\/em><em>News<\/em> reported that: \u201cThe Food and Drug Administration said Monday that Capricor Therapeutics\u2019 stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial \u2014 contrary to the company\u2019s claims last year.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0<\/p>\n<p align=\"justify\">If you purchased Capricor stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LrFtiHdKcaezBD6siozVdgwqUDu1xr_4fRqkmkzCTJ_Kh_mCem8TfNqekkESxEfRWQyIlq1dKJCq7je0P-BjPgOIg0uCs3SeZtOLwndfDkI=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a> or Joshua Karr, Esq. at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w4vMRcLJuyDlHKfo387NK9xWY2CkRJ9XYDDMX7nhJmzHMXCoznBw12v0UBcjhaYw7cEW91iiveFprpbd3xZPfq5TzjEb7rOhQeikHu7FdQ0=\" rel=\"nofollow\" target=\"_blank\"><u>jkarr@holzerlaw.com<\/u><\/a>, call our toll-free number at (888) 508-6832, or visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q1dKMkJgcXiHUPNimnOFU0huvjw7T5I8uStfgkPPzEauqC8AhURMY8iBMc8wmzHWpaouZAmCFycf6bN99pubxOS0x8jBFeOOO0RXdW_kxxQWN7Hg4YUhxWi4RJsAoDYnc32o-Uub_---uCQwNLUQHQ==\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com\/case\/capricor\/<\/a> to discuss your legal rights.<\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q1dKMkJgcXiHUPNimnOFU6OfxbINHB6H8QVrACGWFGY9SUGBTvLfL4WeFxrXgOIuhfr-m_CRxcP96zWyZTNGWcUQbcHjn01s6h2QdlrvEMk=\" rel=\"nofollow\" target=\"_blank\"><u>www.holzerlaw.com<\/u><\/a>,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free) <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LrFtiHdKcaezBD6siozVdgwqUDu1xr_4fRqkmkzCTJ9ey6erbTKKERF2tSo0a1btb2HCEtUynnMMQ30Z5uxx_bleGBBb4BIGurE3Rw7giHM=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjdkMWQ0MGUtYzA5Yy00NGY2LWE1Y2UtZTgwOGMwM2ViMjgyLTExOTIzMzYtMjAyNi0wNy0yNy1lbg==\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, July 27, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR) complied with federal securities laws.\u00a0On July 27, 2026, STATNews reported that: \u201cThe Food and Drug Administration said Monday that Capricor Therapeutics\u2019 stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial \u2014 contrary to the company\u2019s claims last year.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased Capricor stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/capricor\/ to discuss your &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-985111","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, July 27, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR) complied with federal securities laws.\u00a0On July 27, 2026, STATNews reported that: \u201cThe Food and Drug Administration said Monday that Capricor Therapeutics\u2019 stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial \u2014 contrary to the company\u2019s claims last year.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased Capricor stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/capricor\/ to discuss your &hellip; Continue reading &quot;CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-27T17:56:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC\",\"datePublished\":\"2026-07-27T17:56:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/\"},\"wordCount\":257,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/\",\"name\":\"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=\",\"datePublished\":\"2026-07-27T17:56:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/","og_locale":"en_US","og_type":"article","og_title":"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","og_description":"ATLANTA, July 27, 2026 (GLOBE NEWSWIRE) &#8212; Holzer &amp; Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR) complied with federal securities laws.\u00a0On July 27, 2026, STATNews reported that: \u201cThe Food and Drug Administration said Monday that Capricor Therapeutics\u2019 stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial \u2014 contrary to the company\u2019s claims last year.\u201d Following this news, the price of the Company\u2019s stock dropped.\u00a0 If you purchased Capricor stock and suffered\u202fa\u202floss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at\u202fjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com\/case\/capricor\/ to discuss your &hellip; Continue reading \"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-27T17:56:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC","datePublished":"2026-07-27T17:56:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/"},"wordCount":257,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/","name":"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=","datePublished":"2026-07-27T17:56:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5ODY2NiM3NzQ0ODg0IzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capr-investor-alert-investigation-of-capricor-therapeutics-inc-announced-by-holzer-holzer-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer &amp; Holzer, LLC"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=985111"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985111\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=985111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=985111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=985111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}